Blood Screening Market

Escalating Need for Blood Test Recommendations Fuel Market Growth

The Blood Screening Market is valued at USD 3.7 Bn in 2026 and is projected to reach USD 7.9 Bn, growing at a CAGR of 12% by 2033. An alarming rate of prevalence of a variety of infectious diseases is predominantly driving the demand for blood screening. An expanding geriatric population also fuels the market growth as a result of multiple age-related health conditions, and growing susceptibility to chronic illnesses. A consistent increase in the number of blood donation programmes, as well as the soaring frequency of blood transfusions conducted at hospitals, and other healthcare settings further necessitate blood screening, thereby driving the market growth. However, the lack of standardisation regarding blood transfusion procedures, complex regulatory approval framework, and severe dearth of skilled manpower continue to impede rapid market expansion, especially across developing economies. A few alternative testing techniques like digital immunoassay have been emerging as potential substitutes for blood screening over the recent past, which is also expected to pose a challenge to market growth in the near future.

Mandatory blood screening for the presence of red cell antibodies, and infectious disease agents such as HIV-1 and -2, hepatitis virus, T. pallidum (syphilis), human T-lymphotropic virus (HTLV) T. Cruzi, and West Nile virus (WNV) remain an important factor heavily contributing toward the growth of the global blood screening market. More opportunities continue to emerge on the horizon with the promising introduction of microbiology screening and multiplexing for HIV, HBV, and HCV, and pathogen reduction technology. A range of screenings to be conducted during the phases of pregnancy so as to detect any possible prenatal abnormalities will remain another strong factor encouraging the demand for blood screening. The indispensable significance of tests like western blot assay, next generation sequencing (NGS), and enzyme linked immunosorbent assay (ELISA) continues to uphold the flourishing growth prospects of the market.

Although blood screening related to transfusion, and donation experienced a major setback during the initial months of the pandemic, the overall long-term impact of the pandemic is expected to favour the growth of the blood screening market. The American Red Cross has been pioneering blood screening that covers blood, platelets, and plasma for presence of COVID-19 antibodies. Mandatory screening of donated plasma for blood typing tests, and infectious disease agents is also likely to push market growth. The US Food and Drug Administration (FDA)’s emergency use authorisation for around 50 serological tests over utilisation of the convalescent plasma in treatment of hospitalised COVID-19 patients (April, 2020) has been a solid booster to market growth amid the pandemic. There has been constant encouragement for plasma donation, which remains a strong sustaining factor for the market.

Blood Banks Prime Consumer Segment; NAT Retains Dominance over Other Screening Technologies

While blood banks will remain the top end user, hospitals will also continue to register substantial demand for blood screening tests. Among the key products and services covered in the market study, reagents and kits are expected to remain top selling on account of ready accessibility of a wide range of reagents and the critically growing need for specific, faster, and reliable detection of transfusion transmissible infections (TTIs). The segment is specifically driven by the rise in blood transfusion, and donation-related tests, further accelerated by the soaring demand for serological testing amid COVID-19 outbreak. When it comes to analysing the various blood screening technologies, including nucleic acid amplification test (NAT), ELISA, western blot assay, rapid tests, and NGS, it is expected that NAT will remain sought-after among hospitals, blood banks, and testing labs owing to its higher specificity, and sensitivity for viral nucleic acid.

Blood Screening Market Continues to Flourish in Developed Western Regions

North America, followed by Europe, is expected to remain the most significant market in the blood screening landscape on the back of soaring demand for and response to blood donation initiatives, and higher chronic and infectious disease prevalence. The market growth in the region will however receive support from the sophisticated healthcare infrastructure, coupled with the thriving space of diagnostics. Strong presence of a majority of key market players also works to the advantage of market growth in the region. The European market, on the other hand, continues to gain from the favourable regulatory environment. Market players will particularly discover new windows of opportunity in Asia Pacific as the region has been witnessing a lot of government initiatives signifying blood screening in diagnostics, and rising awareness about potential disease transmission through blood transfusion.

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Bio Rad Laboratories
• Danaher Corporation (Beckman Coulter & Cepheid)
• Becton, Dickinson and Company (BD)
• BioMérieux
• Grifols, S.A.
• Ortho Clinical Diagnostics
• Hologic, Inc.
• QuidelOrtho Corporation
• Hoffmann La Roche Ltd.
• PerkinElmer, Inc.
• Sysmex Corporation

Global Blood Screening Market Segmnetation

By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing
• Western Blotting

By Product

• Reagent
• Instrument

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa